Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of $189.20 billion. The enterprise value is $203.65 billion.
| Market Cap | 189.20B |
| Enterprise Value | 203.65B |
Important Dates
The next confirmed earnings date is Tuesday, February 10, 2026, after market close.
| Earnings Date | Feb 10, 2026 |
| Ex-Dividend Date | Dec 15, 2025 |
Share Statistics
Gilead Sciences has 1.24 billion shares outstanding. The number of shares has increased by 1.02% in one year.
| Current Share Class | 1.24B |
| Shares Outstanding | 1.24B |
| Shares Change (YoY) | +1.02% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 89.01% |
| Float | 1.24B |
Valuation Ratios
The trailing PE ratio is 23.74 and the forward PE ratio is 18.45. Gilead Sciences's PEG ratio is 0.80.
| PE Ratio | 23.74 |
| Forward PE | 18.45 |
| PS Ratio | 6.53 |
| Forward PS | 6.22 |
| PB Ratio | 8.79 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 20.65 |
| P/OCF Ratio | 19.57 |
| PEG Ratio | 0.80 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.41, with an EV/FCF ratio of 22.23.
| EV / Earnings | 25.11 |
| EV / Sales | 7.00 |
| EV / EBITDA | 14.41 |
| EV / EBIT | 17.91 |
| EV / FCF | 22.23 |
Financial Position
The company has a current ratio of 1.45, with a Debt / Equity ratio of 1.16.
| Current Ratio | 1.45 |
| Quick Ratio | 1.10 |
| Debt / Equity | 1.16 |
| Debt / EBITDA | 1.74 |
| Debt / FCF | 2.72 |
| Interest Coverage | 11.17 |
Financial Efficiency
Return on equity (ROE) is 40.71% and return on invested capital (ROIC) is 24.42%.
| Return on Equity (ROE) | 40.71% |
| Return on Assets (ROA) | 12.57% |
| Return on Invested Capital (ROIC) | 24.42% |
| Return on Capital Employed (ROCE) | 24.59% |
| Weighted Average Cost of Capital (WACC) | 6.03% |
| Revenue Per Employee | $1.65M |
| Profits Per Employee | $460,795 |
| Employee Count | 17,600 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 3.39 |
Taxes
In the past 12 months, Gilead Sciences has paid $1.78 billion in taxes.
| Income Tax | 1.78B |
| Effective Tax Rate | 17.96% |
Stock Price Statistics
The stock price has increased by +53.04% in the last 52 weeks. The beta is 0.39, so Gilead Sciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | +53.04% |
| 50-Day Moving Average | 127.52 |
| 200-Day Moving Average | 116.77 |
| Relative Strength Index (RSI) | 82.05 |
| Average Volume (20 Days) | 8,106,872 |
Short Selling Information
The latest short interest is 22.97 million, so 1.85% of the outstanding shares have been sold short.
| Short Interest | 22.97M |
| Short Previous Month | 23.15M |
| Short % of Shares Out | 1.85% |
| Short % of Float | 1.86% |
| Short Ratio (days to cover) | 3.62 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of $29.09 billion and earned $8.11 billion in profits. Earnings per share was $6.42.
| Revenue | 29.09B |
| Gross Profit | 22.90B |
| Operating Income | 11.37B |
| Pretax Income | 9.89B |
| Net Income | 8.11B |
| EBITDA | 14.14B |
| EBIT | 11.37B |
| Earnings Per Share (EPS) | $6.42 |
Balance Sheet
The company has $8.49 billion in cash and $24.94 billion in debt, with a net cash position of -$14.45 billion or -$11.64 per share.
| Cash & Cash Equivalents | 8.49B |
| Total Debt | 24.94B |
| Net Cash | -14.45B |
| Net Cash Per Share | -$11.64 |
| Equity (Book Value) | 21.46B |
| Book Value Per Share | 17.34 |
| Working Capital | 5.58B |
Cash Flow
In the last 12 months, operating cash flow was $9.67 billion and capital expenditures -$505.00 million, giving a free cash flow of $9.16 billion.
| Operating Cash Flow | 9.67B |
| Capital Expenditures | -505.00M |
| Free Cash Flow | 9.16B |
| FCF Per Share | $7.38 |
Margins
Gross margin is 78.72%, with operating and profit margins of 39.09% and 27.88%.
| Gross Margin | 78.72% |
| Operating Margin | 39.09% |
| Pretax Margin | 33.99% |
| Profit Margin | 27.88% |
| EBITDA Margin | 48.60% |
| EBIT Margin | 39.09% |
| FCF Margin | 31.50% |
Dividends & Yields
This stock pays an annual dividend of $3.16, which amounts to a dividend yield of 2.07%.
| Dividend Per Share | $3.16 |
| Dividend Yield | 2.07% |
| Dividend Growth (YoY) | 2.60% |
| Years of Dividend Growth | 11 |
| Payout Ratio | 49.20% |
| Buyback Yield | -1.02% |
| Shareholder Yield | 1.05% |
| Earnings Yield | 4.29% |
| FCF Yield | 4.84% |
Analyst Forecast
The average price target for Gilead Sciences is $130.10, which is -14.69% lower than the current price. The consensus rating is "Buy".
| Price Target | $130.10 |
| Price Target Difference | -14.69% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (5Y) | 3.96% |
| EPS Growth Forecast (5Y) | 77.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 28, 2013. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 28, 2013 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Gilead Sciences has an Altman Z-Score of 3.64 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.64 |
| Piotroski F-Score | 7 |